Previously published online as a Cell Cycle E-publication: http://www.landesbioscience.com/journals/cc/abstract.php?id=1520 KEY WORDSsiRNA, transcriptional gene silencing, RNA mediated DNA methylation ACKNOWLEDGEMENTSWe would like to thank Steve Jacobsen, Robert Martienssen, David Baulcombe and John Rossi for their comments, criticisms and valued conversations on RNA mediated transcriptional gene silencing. Review siRNA Induced Transcriptional Gene Silencing in Mammalian Cells ABSTRACTEpigenetics is the study of meiotically and mitotically heritable changes in gene expression which are not coded for in the DNA. 1,2 Three distinct mechanisms appear to be intricately related and implicated in initiating and/or sustaining epigenetic modifications; DNA methylation, RNA-associated silencing, and histone modifications. 2 It has recently become clear in human cells that RNA plays a far more profound and complex role in regulating the expression of the gene. This regulatory effect is through RNA-associated silencing, can be transcriptional in nature, and is operable through an RNA interference based mechanism (RNAi) that is specifically mediated by small-interfering RNAs (siRNAs). Specifically, the recent observations by both our groups that siRNAs can silence target genes at the level of the chromatin in mammalian cells. We discuss here siRNA mediated transcriptional gene silencing and directed DNA methylation as well as the putative mechanism involved in human cells. Undoubtedly, the ramifications from this paradigm shift of RNA regulating the expression of the gene are immeasurable both therapeutically (i.e., directed control of a genes expression) and biologically in understanding the evolution of the cell.

To overcome obstacles to target site selection, we recently created a novel hybrid ribozyme that could access any chosen site by the recruitment of intracellular RNA helicases [Warashina et al. (2001) Proc. Natl. Acad. Sci. USA 98, 5572-5577; Kawasaki et al. (2002) Nat. Biotech. 20, 376-380]. We also demonstrated previously that pol III-driven maxizymes with two substrate-binding arms that were directed against two different sites within a target mRNA formed very active heterodimers in vivo [Kuwabara, et al. (2000) Trends Biotechnol. 18, 462-468; Tanabe et al. (2001) Nature 406, 473-474]. Despite the complicated dimerization process, all the maxizymes that we tested in cultured cells had greater catalytic activity than the parental ribozymes. To investigate the action of maxizymes in cells, we designed a specific maxizyme with two substrate-binding arms that was directed against endogenously expressed LTR-luciferase chimeric mRNA, where LTR refers to the long terminal repeat of HIV-1. One substrate-binding arm of the maxizyme was designed to bind to a site within HIV-1 TAR RNA that is known to form a stable stem structure that normally prevents binding of a ribozyme. The other substrate-binding arm was directed against a relatively accessible site within the luciferase gene. As expected, the conventional ribozyme failed to cleave the TAR region in vivo because of the latter's stable secondary structure. However, to our surprise, the maxizyme cleaved the TAR region within the stem with high efficiency in vivo. The enhanced cleavage in vivo by the maxizyme might have resulted from an entropically favorable, intramolecular, second binding process that occurred during the breathing of the stem structure of the target mRNA. Importantly, our data suggest that this maxizyme technology might be used as an alternative approach to the recruitment of RNA helicases in cleaving sites previously found to be inaccessible.